Understanding the Mechanisms of Resistance in CAR T Immunotherapy for Lymphoma and Strategies to Overcome Them

Join a 59-minute webinar led by Dr. Marco Ruella, Assistant Professor of Medicine at the University of Pennsylvania and Scientific Director of the Lymphoma Program, exploring the complexities of CAR T immunotherapy resistance in lymphoma treatment. Dive deep into the mechanisms behind why only 30-40% of patients maintain durable complete remission after FDA-approved anti-CD19 CAR T cell treatments. Learn about tumor cell-intrinsic factors, CAR T cell dysfunction, and the immunosuppressive tumor microenvironment that contribute to treatment resistance. Discover cutting-edge research findings using next-generation techniques like scRNA sequencing and spatial transcriptomics, and explore innovative approaches to enhance treatment efficacy while reducing toxicity. Examine first-in-human clinical trials combining CAR T19 with ibrutinib and anti-CD19/CD22 CAR T cells, and understand the latest developments in improving outcomes for patients with relapsed or refractory hematologic malignancies. Gain insights into tumor evasion mechanisms and the rational design of novel CAR T approaches that could revolutionize cancer immunotherapy.